StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

(S)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepin

Esmirtazapine

HCID 3085218
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
61337-87-9
Standard-SMILES
CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1
InChIKey
RONZAEMNMFQXRA-MRXNPFEDSA-N
Summenformel
C17H19N3
Durchschnittliche Molmasse
265,35 g/mol
Monoisotopische Masse
265,15789762

Überblick

Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology. This includes inverse agonist activity of H1 and 5-HT2 receptors and antagonism of α2-adrenergic receptors. Merck has terminated its internal clinical development program for esmirtazapine as of March 2010.

Namen und Bezeichner

Bevorzugter Name
Esmirtazapine
IUPAC
(7S)-5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
Lokaler Name
(S)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepin
Englischer Name
(S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
Summenformel
C17H19N3
Molmasse
265.35286

Namen und Synonyme

Esmirtazapine(S)-Mirtazapine61337-87-9(+)-Mirtazapine(s)-6-azamianserinMirtazapine, (s)-(s)-org 3770esmirtazapinaOrg-44-20(S)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine4685R51V7MDTXSID001029320
Weitere Namen anzeigen
(S)-Org3770D3-S-MirtazapineS-(+)-Mirtazapine(+)-(S)-Mirtazapine(S)-Mirtazapine-13C-d3Mirtazapine Impurity 23(S)Mirtazapine,(S) Mirtazapine
(S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepineesmirtazapinumRefChem:137870DTXCID901514590(7S)-5-methyl-2,5,19-triazatetracyclo(13.4.0.02,?.0?,13)nonadeca-1(15),8,10,12,16,18-hexaene262-714-0Esmirtazapine [INN](7S)-5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene

Datenbank-Bezeichner

CAS

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
3,3
Polarare Oberfläche (TPSA)
19,4 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
0
Schwere Atome
20
Formalladung
0
Komplexität
345

Experimentelle und physikochemische Eigenschaften

SolubilitySoluble in methanol and chloroform mg/mL (20 °C)

Physikochemische Eigenschaften

Schmelzpunkt
85 · 85 - 87°C
storage temp.
-20 °C · -20°C Freezer
Löslichkeit
Chloroform (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
Farbe
White to Off-White

Chemie und Industrie

Pharmakologische Informationen

Biological Half-Life10 hours
MeSH Pharmacological Classification · 6 Einträge

Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.

Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood.

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Drugs that bind to and block the activation of ADRENERGIC ALPHA-2 RECEPTORS.

Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.

Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS.

Anwendungen

VerwendenS-Mirtazapine is an enantiomer of Mirtazapine (M365000); an antidepressant. R-Mirtazapine showed antinociceptive effects in acute thermal nociception, whereas S-Mirtazapine showed pronociceptive effects.

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
61337-87-9
PubChem CID
3085218
DTXSID
DTXSID001029320
ChEMBL
CHEMBL1366933
UNII
4685R51V7M
EC Number
262-714-0
Nikkaji
J279.597C